IP Intelligence
Patent Tracker
Who owns the psychedelic drug pipeline — and what's heading off-patent.
By 2030
47
patents expiring
2031–2035
15
patents expiring
2036–2040
52
patents expiring
2041+
97
patents expiring
211 Granted · 466 Pending · 88 Companies
Data pulled from TREA, an IP intelligence platform, as of Aug 17, 2026 — not a live feed. Figures shift as patents are filed, granted, or challenged.
Top patent holders
| Company | Compounds | Granted | Pending | Est. Expiration | Notes |
|---|---|---|---|---|---|
Clearmind Medicine Inc | LSD, Ketamine, Ibogaine, MEAI | 32 | 3 | 2037–2037 | Figures are company-self-reported (19 patent families, 32 granted patents as of June 2026), not compiled via the same patent-database search methodology used for the rest of this dataset — treat as directionally accurate, not a like-for-like comparison with other rows. The 2037 expiration is independently verified for two specific granted sibling patents — US 12,357,590 (granted July 15, 2025, expires Dec 3, 2037) and US 12,350,242 (granted July 8, 2025, expires Oct 31, 2037), both titled "Binge Behavior Regulators," covering MEAI, filed the same day (July 2021) with the same Dec 2014 priority date, per Google Patents — not a portfolio-wide range across all 32 granted patents. The "pending: 3" reflects only the three newly-published US applications covering LSD/ketamine/ibogaine combinations with N-acylethanolamines (PEA), announced Sept 23, 2026, in collaboration with NeuroThera Labs — not a full count of pending filings globally (Clearmind has also filed in Japan and Hong Kong in 2026). |
Compass Pathfinder Limited COMPASS Pathways plc | Psilocybin, LSD | 13 | 21 | 2039–2044 | 10 terminal disclaimers All 12 patent-challenge (PGR/IPR) proceedings in this dataset are against Compass. |
Enveric Biosciences Canada Inc Enveric Biosciences, Inc. | Psilocybin | 12 | 18 | 2042–2044 | 3 terminal disclaimers |
Turtle Bear Holdings, LLC | Psilocybin, 5-MeO-DMT | 10 | 15 | 2038–2043 | 7 terminal disclaimers Private LLC (associated with Paul Stamets); not publicly traded. |
Beckley Psytech Limited Eli Lilly and Company (formerly AtaiBeckley Inc., formerly atai Life Sciences AG, merged with Beckley Psytech Nov 2025) | 5-MeO-DMT, DMT | 8 | 8 | 2042–2044 | 2 terminal disclaimers Beckley Psytech was never independently listed. Parent AtaiBeckley's acquisition by Eli Lilly (~$2.8B upfront, up to $3.8B with milestones) closed Sept 11, 2026, per Lilly's own press release — AtaiBeckley is now a wholly-owned Lilly subsidiary. Reported (not Lilly-confirmed): AtaiBeckley asked Nasdaq to file a Form 25 to delist its ATAI shares. |
CaaMTech, LLC | Psilocybin, DMT, 5-MeO-DMT, Ibogaine | 7 | 18 | 2038–2043 | 1 terminal disclaimer Private; not publicly traded. |
Amorsa Therapeutics, Inc. | Ketamine | 7 | 8 | 2034–2042 | 3 terminal disclaimers Private; reportedly no longer active. |
Small Pharma Ltd Helus Pharma (acquired by Cybin, now Helus Pharma, Oct 2023) | DMT, 5-MeO-DMT, Ketamine | 6 | 16 | 2040–2042 | 3 terminal disclaimers Delisted from TSXV in 2023 following the Cybin acquisition; no longer independently traded. |
Cybin UK Ltd Helus Pharma (formerly Cybin Inc.) | DMT, 5-MeO-DMT | 6 | 4 | 2040–2043 | 5 terminal disclaimers Parent renamed from Cybin/CYBN to Helus Pharma and moved from NYSE American to Nasdaq (HELP) in Jan 2026. |
DemeRx, Inc. | Ibogaine | 5 | 20 | 2031–2037 | Private; not publicly traded. |
University of Arkansas Board of Trustees | MDMA | 5 | 2 | 2027–2032 | 3 terminal disclaimers 4 of 5 grants expire by 2030. |
Roche Holding AG | LSD | 5 | 0 | 2017–2026 | All already expired or expiring this year. Roche's SIX-listed non-voting equity security converted from its old Genussschein (formerly traded as RO) to new participation certificates (ROPC) in March 2026. |
Universitätsspital Basel | Psilocybin, LSD, MDMA, DMT, 5-MeO-DMT | 4 | 12 | 2041–2042 | Broadest compound spread of any academic holder. |
West Virginia University | Ketamine | 4 | 6 | 2035–2043 | 2 terminal disclaimers |
Zylorion Health Inc. | Psilocybin | 4 | 3 | 2042–2044 | 4 terminal disclaimers All 4 grants carry terminal disclaimers. No public listing found. |
Psilera Inc. | Psilocybin, DMT, 5-MeO-DMT | 3 | 6 | 2041–2043 | |
Atai Therapeutics, Inc. Eli Lilly and Company (formerly AtaiBeckley Inc., formerly ATAI Life Sciences AG) | Psilocybin, Ibogaine, DMT, 5-MeO-DMT | 3 | 6 | 2042–2043 | Distinct from the parent entity's own separate filings (1 grant, 14 applications). Parent AtaiBeckley's acquisition by Eli Lilly closed Sept 11, 2026, per Lilly's own press release — AtaiBeckley is now a wholly-owned Lilly subsidiary. |
National University Corporation | Ketamine | 3 | 5 | 2034–2039 | 2 terminal disclaimers |
XWPharma Ltd. | Ketamine | 3 | 2 | 2040–2042 | Affiliated with XW Laboratories Inc. (2 separate grants). No confirmed public listing despite earlier IPO plans. |
Psilo Scientific Ltd. | Psilocybin, 5-MeO-DMT | 3 | 1 | 2041–2042 | |
Terran Biosciences Inc. | Psilocybin, LSD, MDMA, DMT, 5-MeO-DMT | 2 | 13 | 2043–2043 | Application-heavy relative to its grants. Private, despite past SPAC speculation. |
Janssen Pharmaceutica N.V. Johnson & Johnson (Innovative Medicine) | Ketamine | 2 | 11 | 2038–2038 | The Spravato (esketamine) franchise. |
Develco Pharma Schweiz AG | Ketamine | 2 | 4 | 2035–2039 | |
Lennham Pharmaceuticals, Inc. | Psilocybin | 2 | 3 | 2040–2041 | |
XW Laboratories Inc. | Ketamine | 2 | 3 | 2039–2040 | |
Cooper Health System, Inc. | Ketamine | 2 | 3 | 2032–2036 | |
SRI International, Inc. | Ketamine | 2 | 3 | 2032–2036 | Co-assigned with the US Department of Health and Human Services. |
US Department of Health and Human Services | Ketamine | 2 | 3 | 2032–2036 | |
Université de Liège | Ketamine | 2 | 2 | 2040–2042 | |
University of Minnesota | Ketamine, Ibogaine | 2 | 1 | 2015–2038 | One grant already expired. |
Randox Laboratories Limited | MDMA, Ketamine | 2 | 0 | 2022–2023 | Detection/immunoassay patents, not therapeutics — both already expired. Privately held. |
NDA International, Inc. | Ibogaine | 2 | 0 | 2008–2010 | The original Howard Lotsof ibogaine patents, long expired. |
NRx Pharmaceuticals, Inc. | Ketamine | 0 | 1 | 2045–2045 | Covers only the one ketamine-specific filing: a US patent application filed June 5, 2025 for NRX-100, NRx's preservative-free IV ketamine formulation, seeking protection through 2045 if granted — not yet granted as of this writing. NRx's much larger reported portfolio (48 issued patents, 16 filed applications per its FY2023 10-K) is almost entirely unrelated: those cover NRX-101 (an oral D-cycloserine/lurasidone combination) and a licensed D-cycloserine pain patent, not ketamine, and are deliberately excluded here so they don't inflate this dataset's ketamine patent count. Separately, NRx's generic preservative-free ketamine product, KETAFREE, won FDA approval via the ANDA pathway on Oct 30, 2026 — that's a generic-drug approval, not a patent, and rests on ketamine being off-patent since the 1970s rather than on any IP NRx holds. See our ketamine patent gap coverage (journal #23) and the KETAFREE news item for more. |
Everyone else
56 companies hold exactly one granted patent each. The application-heavy ones stand out more than the grant itself: GH Research Ireland (Nasdaq: GHRS; 1 grant, 26 pending — the most application-heavy holder in the set), Definium Therapeutics — renamed from MindMed in January 2026 (Nasdaq: DFTX; 1 + 18), ATAI Life Sciences AG — now a wholly-owned Eli Lilly subsidiary after the AtaiBeckley acquisition closed Sept 11, 2026 (NYSE: LLY; 1 + 14), Mydecine — renamed Noveris Health Sciences in Feb 2026 (1 + 6), and Pfizer (NYSE: PFE; 1 grant, expired 2010).
Application-only, no grants yet: Columbia University (5), Cybin IRL (5), Diamond Therapeutics (3), Silo Pharma (3), Mount Sinai (3), Ceruvia Lifesciences (3).
A further 27 patents with no listed assignee — mostly early inventor-held ketamine filings, not a company — aren't shown in the table above.
By compound
Granted / pending applications. Compounds overlap — one patent can count toward several.
Ketamine
71 / 117
Psilocybin
60 / 163
5-MeO-DMT
52 / 112
DMT
40 / 86
Ibogaine
15 / 38
LSD
14 / 34
MDMA
11 / 38
Worth watching
All 12 patents in this dataset citing post-grant or inter partes review proceedings belong to Compass Pathfinder (COMPASS Pathways) — petitions filed by Freedom To Operate, Inc. against its psilocybin polymorph patents. Compass also carries the heaviest terminal-disclaimer load of any holder (10 of 13). Its portfolio nominally runs to 2044, but it's the most legally contested position in the set.
Coverage & Caveats
- Four keyword searches — psilocybin, LSD, ketamine, and DMT — hit a page-fetch cap on TREA and still showed further results available, so those counts are floors, not totals. MDMA, ibogaine, and DMT-analog searches completed in full.
- 5-MeO-DMT has no clean search key on TREA — it tokenizes into unrelated results — so that figure was recovered via a related-compound search plus manual filtering, making it the least reliable row here.
- The expiration range is a rough filing-date-plus-20-years estimate. It ignores Patent Term Adjustment (which extends real dates) and is simply wrong wherever a terminal disclaimer applies — 56 of 211 grants (27%) carry one, tying their real expiration to an earlier sibling patent instead.
- "Compounds covered" is mention-level, not claim-level — a patent can list a compound in its body text (e.g. as one analog among many in a broad chemistry patent) without that compound being its primary claim.
Source: TREA, an IP intelligence platform. Figures above trace to specific patent and application records, not estimates beyond the stated 20-year expiration approximation.